• Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association

    Source: Nasdaq GlobeNewswire / 30 Sep 2021 08:06:29   America/New_York

    WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, announced today that two posters featuring preclinical data on VRDN-001 and VRDN-002 are scheduled to be presented at the 90th Annual Meeting of the American Thyroid Association (ATA), which is being held from September 30th through October 3rd.

    Poster Presentation Details:
    Title:VRDN-002, A Second-Generation Insulin Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease: Preclinical Pharmacokinetic Profile and Clinical Promise
    Poster: #37
    Poster Session (1): Thursday Poster Review Session
    Time and Date:Thursday, September 30, 2021, 12:15-1:00 p.m. EDT (Virtual Poster)
    Poster Session (2): Thursday Highlighted Posters Session #3
    Time and Date:Thursday, September 30, 2021, 4:00-5:00 p.m. EDT
      
    Title:Characterization of VRDN-001, a High Affinity and Potent anti-IGF-1R Inhibitory Antibody in Development for the Treatment of Thyroid Eye Disease
    Poster #:#187
    Poster Session:Saturday Poster Review Session
    Time and Date:Saturday, October 2, 2021, 1:00-2:00 p.m. EDT

    About Viridian Therapeutics, Inc.

    Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

    Viridian Contacts:

    Investors:
    Dan Ferry
    LifeSci Advisors
    617-430-7576
    IR@viridiantherapeutics.com

    Media:
    Darby Pearson
    Verge Scientific Communications
    703-587-0831
    PR@viridiantherapeutics.com

    Source: Viridian Therapeutics, Inc.


    Primary Logo

Share on,